Ross River virus-specific CD4+ T-cell receptor (RRV-specific CD4+ TCR)

CD4+ T-cell receptors (TCRs) recognizing Ross River virus (RRV) peptides are essential mediators of the adaptive immune response to RRV, an alphavirus prevalent in Australia and the Pacific (Zaid et al., 2021, Nature Reviews Immunology). These receptors bind to viral epitopes, such as those derived from the E2 glycoprotein, when presented by Major Histocompatibility Complex (MHC) class II molecules on antigen-presenting cells (PubMed, 2023). Upon binding, the TCR initiates a signaling cascade that activates the CD4+ T cell, leading to the secretion of pro-inflammatory cytokines like interferon-gamma and TNF-alpha. While these cells are necessary for controlling viral replication, their persistent activation is a primary driver of the debilitating joint inflammation and muscle pain characteristic of Ross River fever (Burrack et al., 2015, Journal of Virology). Consequently, these TCRs are significant targets for research into vaccines and immunomodulatory therapies aimed at preventing chronic arthralgia. Understanding the TCR repertoire and epitope specificity is crucial for developing precision medicine approaches to manage alphavirus-induced inflammatory diseases (NCBI, 2022). These receptors represent a key interface between the viral pathogen and the host's pathological immune response.

Other names

Ross River virus-specific T-cell receptorMHC class II-restricted RRV-specific TCRRRV-reactive CD4+ TCRCD4+ T-cell receptor recognizing Ross River virus-derived peptides

The TCR complex recognizes specific Ross River virus peptides (typically derived from the E2 or capsid proteins) presented by MHC class II molecules, triggering intracellular signaling via the CD3 complex to initiate T-cell proliferation and the secretion of pro-inflammatory cytokines (Zaid et al., 2021, Nature Reviews Immunology).